Posted inAllergy & Immunology Dermatology news
Litifilimab Shows Promising Efficacy and Safety in Treating Cutaneous Lupus Erythematosus: Insights from the AMETHYST Phase 2 Trial
The AMETHYST Phase 2 trial demonstrated that litifilimab significantly improves skin symptoms in cutaneous lupus erythematosus with a favorable safety profile, marking a potential new targeted treatment for this challenging condition.